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Abstract Parkinson’s disease (PD) is associated with an
increased risk of fragility fracture. FRAX and Qfracture are
risk calculators that estimate the 10-year risk of hip and
major fractures and guide definitive investigation for
osteoporosis using dual X-ray absorptiometry (DEXA)
imaging. It is unclear which PD patients should be con-
sidered for fracture risk assessment and whether FRAX or
Qfracture should be used. Seventy-seven patients with PD
were recruited in the movement disorders clinic. Data were
collected on PD-related characteristics and fracture risk
scores were calculated. Patients with previous osteoporotic
fractures had a higher incidence of falls (p = 0.0026) and
use of bilateral walking aids (p = 0.0187) in addition to
longer disease duration (p = 0.0037). Selecting patients
with falls in combination with either disease duration
[5 years, bilateral walking aids, or previous osteoporotic
fracture distinguished patients with and without previous
osteoporotic fracture with specificity 67.7 % (95 % CI
55.0–78.8) and sensitivity 100.0 % (95 % CI 73.5–100.0).
Qfracture calculated significantly higher fracture risk
scores than FRAX for hip (p \ 0.0001) and major
(p = 0.0008) fracture in PD patients. Receiver operating
characteristic curves demonstrated that FRAX outper-
formed Qfracture with an area under the curve of 0.84
(95 % CI 0.70–0.97, p = 0.0004) for FRAX and 0.68
(95 % CI 52–86, p = 0.0476) for Qfracture major fracture
risk calculators. We suggest that falls in combination with
either a disease duration longer than 5 years or bilateral
walking aids or previous osteoporotic fracture should be
used as red flags in PD patients to prompt clinicians to
perform a FRAX fracture risk assessment in the neurology
clinic.
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Introduction
Parkinson’s disease (PD) is associated with an increased
risk of fragility fracture [1, 2]. The Global Longitudinal
Study of Osteoporosis in Women (GLOW) found the
association of fracture with PD was stronger than for any
other co-morbidity [3]. The 2-year fracture rate was 16 %
in female PD patients, with an age-adjusted hazard ratio for
incident fracture of 2.2 in PD patients compared to con-
trols. This has been accounted for by a higher incidence of
both falls and reduced bone mineral density in PD [4].
Falls increase in frequency with disease progression, and
meta-analyses suggest that 46 % of all PD patients fall
within a 3-month period [5]. Several motor and non-motor
features have been identified as contributing to falls,
including postural instability, gait disturbance, cognitive
impairment, postural hypotension and urinary symptoms
[6, 7]. Additionally, reduced bone mineral density is
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common in PD and can be diagnosed using dual X-ray
absorptiometry (DEXA) imaging [8]. A recent study of 186
patients with early PD demonstrated that 11.8 % of patients
had osteoporosis (T-score less than -2.5) and 41.4 % had
osteopenia (T-score between -1 and -2.5) [9]. Immobil-
ity, vitamin D deficiency, use of dopaminergic treatments
and reduced nutritional intake contribute to reduced bone
mineral density in PD.
Fragility fractures are a significant cause of morbidity.
Measures to assess and reduce fracture risk in PD are
essential [10]. Several fracture risk calculators, including
FRAX and Qfracture, have been validated and are freely
available via the internet. These estimate the 10-year risk
of either hip fracture or major fracture using clinical risk
factors for osteoporosis, including the body mass index
(Table 1). FRAX was developed using nine international
population-based prospective cohorts [11], whereas
Qfracture was derived from prospective primary care data
collected in the UK [12]. In contrast to FRAX, the
Qfracture algorithm includes PD as a specific risk factor for
osteoporotic fractures.
The National Institute for Clinical Excellence (NICE)
recommends that fracture risk assessment using either
FRAX or Qfracture should be considered in all patients
with possible secondary osteoporosis, and that these should
be used to determine who should undergo formal bone
mineral density measurement using DEXA imaging [13].
Recommendations on the risk threshold at which a patient
requires this investigation are not included. Guidelines on
the primary prevention of osteoporotic fractures state that
those patients with osteoporosis (T-score less than -2.5)
should be offered bisphosphonates as first-line treatment if
they have an appropriate number of clinical risk factors for
osteoporosis according to their age group [14].
There remains uncertainty as to which PD patients
should have an assessment of their fracture risk. Moreover,
FRAX or Qfracture have not been directly compared in PD
patients. This service development study firstly aims to
establish red flags, specific to PD patients, which should
prompt a fracture risk assessment using a risk calculator.
Secondly, it aims to determine which risk calculator should
be used in this patient group in the outpatient clinic.
Methods
This study was approved by the Clinical Effectiveness Unit
at Barts Health NHS Trust (project reference 578-13). PD
patients diagnosed according to the Queen Square Brain
Bank criteria [15] were assessed. Sufficient data for FRAX
and Qfracture risk calculations were collected (Table 1)
through patient interviews and a review of the medical
records following informed consent from each patient.
Data were also collected on previous osteoporotic frac-
tures, falls, duration of disease, disease severity (using
Hoehn–Yahr stage), motor fluctuations, gait freezing, uri-
nary symptoms, cognitive impairment, use of dopaminer-
gic drugs and osteoporosis-related outcome measures
including previous DEXA imaging and treatment with
bisphosphonates.
Fracture risk scores were calculated using FRAX and
Qfracture 10-year risk for both ‘‘hip’’ and ‘‘major’’ (hip,
wrist, shoulder or vertebra) fracture. Osteoporotic fracture
is defined by FRAX as any fracture either occurring
spontaneously in adult life, or arising from trauma, which
in a healthy individual would not have resulted in fracture.
However, Qfracture defines osteoporotic fracture as a
‘‘major fracture’’ occurring in this context. Satisfaction of
both of these criteria was required in order to classify a
patient as having a previous osteoporotic fracture for this
study. In those patients without a recorded body mass index
and unable to give their height and weight, these were
Table 1 Data used in the calculation of FRAX and Qfracture risk
scores
FRAX Qfracture
Age Age
Sex Sex
Weight, height; BMI Weight, height; BMI
Previous fracture Previous fragility fracture
Parental hip fracture Parental osteoporosis or hip fracture
Current smoking Current/previous smoking, number of
cigarettes
Glucocorticoid exposure Regular glucocorticoid exposure
Rheumatoid arthritis Rheumatoid arthritis or SLE
Secondary osteoporosis Alcohol units/day
Alcohol ([3 units/day) Ethnicity
Femoral DEXA
(if available)
Diabetes
Nursing/care home residence
Falls
Dementia
Cancer
Asthma/COPD
Heart attack, angina, stroke or TIA
Chronic liver disease
Chronic kidney disease
Parkinson’s disease
Malabsorption including Crohn’s disease
Endocrine problems
Epilepsy/anticonvulsant exposure
Anti-depressants
Oestrogen-only HRT
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measured and body mass index was calculated according to
a standard formula. There is an upper weight limit for
FRAX and those patients exceeding this weight were
recorded at the maximum 125 kg.
Categorical data on PD-specific characteristics of those
with or without previous osteoporotic fracture were com-
pared using Fisher’s exact test. Data distributions were
assessed for normality using the Shapiro–Wilk test. Non-
parametric unpaired group data were compared using the
Mann–Whitney U test and paired data with the Wilcoxon
signed-rank matched pairs test. Agreement between indi-
vidual scores and systematic error between risk calculators
was assessed using Bland–Altman plots. Receiver operat-
ing characteristic (ROC) curves were plotted to compare
the trade-off between sensitivity and specificity for each
fracture risk calculator in distinguishing patients with or
without previous osteoporotic fractures. The area under the
curve (AUC) was calculated as measure of the performance
of each risk calculator. The sensitivities and cut-off values
for each fracture risk calculator in distinguishing patients
with and without previous osteoporotic fracture were also
compared at specificities of 80, 85 and 90 %. Statistical
analysis was performed using GraphPad Prism Version 6.
Results
Data were collected on 78 patients, one of whom was
excluded on the basis that the diagnosis was changed to
multi-system atrophy at a subsequent clinic visit. The mean
age was 66.7 years (SD 10.3, range 43–85) and 64.9 % of
the subjects were male, consistent with the gender distri-
bution of PD patients in the UK [16]. The median disease
duration was 6 years (range 0–30) and the median Hoehn–
Yahr stage was 2 (range 1–5). Levodopa treatment was
recorded for 97.4 % and dopamine agonists for 48.6 % of
patients at the time of data collection. History of osteo-
porotic fracture was recorded for 15.6 % of patients, with
83.3 % of these occurring after PD diagnosis. Of these 12
patients, three had undergone DEXA imaging in primary
care and were taking bisphosphonates. Multiple osteopo-
rotic fractures since diagnosis were recorded in the same
three patients (Table 2).
In comparing those patients with and without a previous
osteoporotic fracture, there were several PD-related char-
acteristics that differed significantly between the two
groups. Falls occurred in all patients with a previous
osteoporotic fracture, compared to 55 % of patients with-
out a previous fracture (p = 0.0026). In all patients with
previous osteoporotic fractures at least one fracture had
been associated with falls. Those patients with previous
osteoporotic fractures had longer disease duration; median
disease duration was 8.5 years in those with osteoporotic
fracture compared to 5.0 years in those without
(p = 0.0037). The use of walking aids was not significantly
different between the two groups (p = 0.11). However,
50 % of those in the fracture group used bilateral walking
aids, defined as two sticks, a frame or a wheelchair, com-
pared to 16 % of patients without a previous osteoporotic
fracture (p = 0.019). The Hoehn–Yahr stage, the use of
levodopa and the presence of motor fluctuations, gait
freezing, cognitive impairment or urinary frequency were
not significantly different between the two groups
(Table 3).
Selecting patients with falls in combination with both
disease duration longer than 5 years and use of bilateral
walking aids distinguished those with and without previous
osteoporotic fracture with specificity of 95.2 % (95 % CI
Table 2 Osteoporotic fractures
recorded in this cohort
Age (years) and
gender
Site of osteoporotic
fractures
10-year fracture risk (%) Falls Bilateral
walking aid
Disease
duration
(years)FRAX Qfracture
Major Hip Major Hip
73m Hip 22.0 18.0 99.9 99.9 4 4 10
79f Hip 25.0 8.8 37.4 37.4 4 4 2
73m Shoulder 11.0 4.9 24.2 24.2 4 10
76f Shoulder 62.0 54.0 82.6 76.1 4 8
74f Shoulder, vertebra 32.0 15.0 22.9 20.1 4 4 12
79f Shoulder, wrist 37.0 18.0 69.9 69.9 4 7
69m Vertebra 10.0 2.7 7.0 4.8 4 4 30
78f Vertebra 24.0 8.6 14.0 13.4 4 4 8
76f Wrist 19.0 5.5 6.5 6.5 4 4 20
61m Wrist 5.2 0.6 2.5 1.2 4 8
84m Wrist 13.0 7.0 72.6 72.6 4 6
65m Wrist, vertebra 11.0 2.5 32.4 32.4 4 9
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86.7–99.0) and sensitivity of 41.7 % (95 % CI 15.2–72.3).
When falls in combination with either disease duration
longer than 5 years or use of bilateral walking aids was
used, this gave a specificity of 67.7 % (95 % CI 55.0–78.8)
and sensitivity of 100.0 % (95 % CI 73.5–100.0). This
result was unchanged when considering patients with falls
in combination with either disease duration longer than
5 years or use of bilateral walking aids or a previous
osteoporotic fracture.
The 10-year hip and major fracture risk calculations
were compared between FRAX and Qfracture for each PD
patient. The Qfracture risk scores were significantly higher
than the FRAX risk scores for both hip fractures
(p \ 0.0001) and major fractures (p = 0.0008) (Fig. 1).
The median major fracture risk score was 12.0 (range
0.4–99.9) with Qfracture and 8.2 (range 2.2–62.0) with
FRAX. The median hip fracture risk score was 6.5 (range
0.0–99.9) with Qfracture and 2.0 (range 0.1–54.0) with
FRAX. Bland–Altman plots for both hip and major fracture
risk demonstrate that fracture risk calculations are rela-
tively similar between FRAX and Qfracture in patients
with low fracture risks, but that the difference between the
calculations is much greater in patients at higher risks of
fracture (Fig. 2).
Table 3 Comparison of PD-related characteristics in those patients with and without previous osteoporotic fracture
All patients (n = 77) Patients with previous
osteoporotic fracture (n = 12)
Patients without previous
osteoporotic fracture (n = 65)
p value
Falls 62 % (48) 100 % (12) 55 % (36) 0.0026
Disease duration (years, median) 6 8.5 5 0.0037
Bilateral walking aid 22 % (16) 50 % (6) 16 % (10) 0.0187
Hoehn–Yahr stage (median) 2 3 2 0.0921
Walking aid 44 % (32) 58 % (7) 33 % (20) 0.1120
Urinary frequency 47 % (36) 67 % (8) 43 % (28) 0.2077
Motor fluctuations 56 % (43) 50 % (6) 57 % (37) 0.3641
Cognitive impairment 19 % (15) 25 % (3) 18 % (12) 0.6928
Gait freezing 47 % (36) 50 % (6) 46 % (30) 1.0000
Levodopa treatment 97 % (75) 100 % (12) 97 % (63) 1.0000
Percentages are shown with actual numbers in brackets. The Mann–Whitney test was used to determine the p values for disease duration and
Hoehn–Yahr stage. The Fisher’s exact test was used to determine the p values for the remaining characteristics
Fig. 1 Scatter plot of 10-year fracture risk scores for each calculator.
The error bars represent the interquartile range and median. The
Wilcoxon matched pairs signed-rank test was used to determine the
p values
Fig. 2 Bland–Altman plots comparing FRAX and Qfracture risk
scores for a hip fracture and b major fracture. The mean fracture risk
represents that of the FRAX and Qfracture risk scores for each
individual patient
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When comparing the risk calculations from each cal-
culator between those with or without previous osteopo-
rotic fracture, ROC curves for each risk calculator
illustrate that the FRAX calculators, for hip or major
fractures, appear to be superior to the Qfracture calculator
(Fig. 3). The FRAX major fracture and hip fracture risk
calculators performed similarly with an AUC for FRAX
major fracture of 0.84 (95 % CI 0.70–0.97, p = 0.0004)
and an AUC for FRAX hip fracture of 0.84 (95 % CI
0.69–0.98, p = 0.0004). AUC was 0.68 (95 % CI
0.52–0.86, p = 0.048) for the Qfracture major calculator
and 0.76 (95 % CI 0.62–0.91, p = 0.0055) for the
Qfracture hip calculator. In addition, fracture risk calcu-
lations were performed without the contribution from
previous fracture, and the resulting fracture risk values
were used to generate ROC curves for each calculator.
Using this approach, the FRAX AUC values remained
higher than those of Qfracture with a FRAX major frac-
ture AUC of 0.73 (95 % CI 0.55–0.90, p = 0.012) and
FRAX hip fracture AUC of 0.77 (95 % CI 0.61–0.94,
p = 0.0029). When comparing the sensitivity of each
fracture risk calculator at given specificities, FRAX had
higher sensitivity than Qfracture at specificities of 80, 85
and 90 % (Table 4).
Discussion
Falls were present in all patients with an osteoporotic
fracture. Additionally, longer disease duration and use of
bilateral walking aids were significantly more common in
those with fractures compared to those without. The
combination of these factors performed well (sensitivity
and specificity) in identifying those patients that developed
fractures and can be used as ‘‘red flags’’ to prompt clini-
cians to perform fracture risk assessments. We recommend
fracture risk assessment in all PD patients with falls who
either use bilateral walking aids, have a disease duration
[5 years or who have had a previous osteoporotic fracture
(Fig. 4).
In contrast to a recent study by Cheng et al. [17] we did
not find an association with Hoehn–Yahr stage or indeed
with the presence of motor fluctuations, gait freezing,
cognitive impairment or urinary frequency; these are not,
therefore, included as red flags. The limited sample size
and small number of patients with previous osteoporotic
fractures may explain why some of these potential pre-
dictors were not significant. Importantly, using bilateral
walking aids and disease duration as red flags alone
identified all patients with previous osteoporotic fracture
in this study, as reflected by 100 % sensitivity (Table 2).
Nonetheless, it is important to include previous osteopo-
rotic fracture itself as a red flag given that it clearly
increases the risk of further fractures. From our cohort, the
proposed red flags would prompt fracture risk assessment
in 44 % of PD patients in the movement disorders clinic;
however, this is likely to be less in a general neurology
clinic.
An important question is whether all patients with PD
should have a fracture risk assessment. Given that the use
of a fracture risk calculator requires a risk threshold above
which one would decide to investigate using DEXA
imaging, an appreciation of the number of patients above a
given threshold is required to understand the cost impli-
cations of calculating fracture risk on all PD patients. The
National Osteoporosis Guideline Group (NOGG) who
developed FRAX suggest that intervention with alendro-
nate is cost-effective above a FRAX major fracture risk
Fig. 3 Receiver operating characteristics (ROC) curves for each
fracture risk calculator in distinguishing patients with or without
previous osteoporotic fracture
Table 4 Sensitivities and cut-
off values for each fracture risk
calculator at specificities of 80,
85 and 90 %
The 95 % confidence intervals
are given
80 % specificity 85 % specificity 90 % specificity
Sensitivity Cut-off Sensitivity Cut-off Sensitivity Cut-off
FRAX-major 63.6 (30.8–89.1) [13.5 63.6 (30.8–89.1) [15.5 63.6 (30.8–89.1) [16.5
Qfracture-major 45.5 (16.8–76.2) [31.9 27.3 (6.0–61.0) [31.9 27.3 (6.0–61.0) [44.0
FRAX-hip 72.7 (39.0–94.0) [4.2 72.7 (39.0–94.0) [4.75 63.6 (30.8–89.1) [5.5
Qfracture-hip 63.6 (30.8–89.1) [19.6 36.4 (10.9–69.2) [32.55 36.4 (10.9–69.2) [37.3
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threshold of 7 % [18]. By way of example, a threshold with
the FRAX major fracture risk calculator of 10 % would
amount to around one-third of all PD patients undergoing
DEXA imaging in our cohort, around half of whom have
red flags. At higher thresholds, multiple patients with red
flags would not have qualified for imaging. In the absence
of clear guidance, the implementation of the aforemen-
tioned red flag system is a cost-effective approach to
identifying those PD patients that require DEXA imaging.
When comparing different fracture risk calculators,
Qfracture produced significantly higher risk scores than
FRAX, particularly in high-risk patients. The opposite is
seen when comparing these calculators in patients with
multiple sclerosis (MS) and this may be accounted for the
by the inclusion of PD but not MS in Qfracture [19].
Despite this, the FRAX calculators appeared to be superior
to the Qfracture calculators in this cohort, as measured by
the area under the ROC curves and the comparison of the
sensitivities of each calculator at given specificities. A
limitation of this analysis, in addition to the size of the
study, is that to assess the performance of each calculator,
we compared the risk scores from those patients with
previous osteoporotic fractures to those without; previous
osteoporotic fracture is, in itself, an input for each of the
calculators. One might, therefore, argue that different
weightings for this variable between each calculator could
account for the different risk scores. However, if the risk
scores from these two groups are again compared, but all
patients are classified as without previous fracture (for the
purposes of the calculation) then FRAX continues to out-
perform Qfracture.
These findings are counter-intuitive given that Qfrac-
ture includes 26 input variables, including PD and falls,
whereas FRAX uses only 12 variables and does not
include PD or falls. One possible explanation is that our
cohort, consisting of patients requiring regular specialist
follow-up, may have more complex disease compared to
the primary care population used to derive and validate
Qfracture. Falls, dementia, anti-depressant use and nurs-
ing home residence are each included as risk factors in
Qfracture and are more likely to occur in advanced PD.
The use of Qfracture in patients with advanced PD could,
therefore, create a tendency to overestimate fracture risk.
Regardless, given the significant disparity between risk
scores in PD patients using FRAX and Qfracture consis-
tent use of one calculator is required to stratify patients in
this population according to fracture risk. On the basis of
the results above, we would recommend the use of the
FRAX calculators in the neurology outpatient clinic. This
study did not examine the use of these calculators in
primary care and we would, therefore, advocate empirical
use of Qfracture in PD patients in this setting until more
evidence is available.
Osteoporotic fracture can be catastrophic for PD
patients, and identifying those at the highest risk is of the
utmost importance to their management [10]. The use of
fracture risk calculators to guide decisions regarding
DEXA imaging, and therefore, pharmacotherapy, is cru-
cial; however, the value of non-pharmacological mea-
sures in reducing fracture risk in PD should not be
underestimated [20]. These include exercise pro-
grammes, dietary advice, smoking cessation, medication
review and measures to reduce the risk of falls such as
occupational and physiotherapy, visual assessment and
falls education and risk management [2]. Alternative
causes of secondary osteoporosis such as hyperthyroid-
ism, hyperparathyroidism, osteomalacia and hypogonad-
ism should also be considered prior to initiating
bisphosphonate therapy. Serum calcium and vitamin D
levels should be corrected and those at risk of reduced
dietary intake should receive supplementation. NICE
guidance recommends alendronic acid as a first-line
bisphosphonate [14], and those patients who cannot
comply with instructions to remain upright for at least
30 min following administration (prior to breakfast),
those with persistent upper gastrointestinal disturbance as
a result of alendronate and those with contraindications
such as oesophageal disease that delays emptying should
receive risedronate or etidronate. In patients with PD,
care should be taken in those with dysphagia who may
exhibit delayed oesophageal emptying.
Ultimately, an integrated approach including pharma-
cological and non-pharmacological measures to improve
bone mineral density and falls reduction strategies in
combination with fracture risk assessments is required to
prevent osteoporotic fractures in PD [4].
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Fig. 4 Red flags to prompt fracture risk assessment in PD
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